Katherine High
MD
President, Therapeutics, Asklepios BioPharmaceutical; Former President and Chief Scientific Officer, Spark Therapeutics
👥Biography 个人简介
Katherine High led the translation of AAV gene therapy from laboratory to clinical use including the approval of Luxturna, the first gene therapy approved in the United States. She co-founded Spark Therapeutics and now leads therapeutics at Asklepios BioPharmaceutical. She is one of the foremost figures in clinical AAV translation.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Katherine High 的研究动态
Follow Katherine High's research updates
留下邮箱，当我们发布与 Katherine High（Asklepios BioPharmaceutical）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment